{"preliminary_commentary":{"by_channel":{"youtube":11,"x_thread":7,"podcast":5,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04332822\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["R-pola-mini-CHP"]],"indication":"diffuse large B-cell lymphoma, ≥80 or frail ≥75","name":"POLAR BEAR","nct_id":"NCT04332822","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=polar-bear-nct04332822. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"POLAR BEAR","arms":[{"description":"Cycles 1-6, duration 21 days\n\n* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6\n* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6\n* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6\n* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6\n* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6","label":"Arm A - R-mini-CHOP","type":"ACTIVE_COMPARATOR"},{"description":"Cycles 1-6, duration 21 days\n\n* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6\n* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6\n* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6\n* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6\n* Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6","label":"Arm B - R-pola-mini-CHP","type":"EXPERIMENTAL"}],"collaborators":["Roche Pharma AG"],"completion_date":{"date":"2028-12-28","type":"ESTIMATED"},"conditions":["DLBCL","Diffuse Large B Cell Lymphoma"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"R-pola-mini-CHP","otherNames":[],"type":"DRUG"},{"name":"R-mini-CHOP","otherNames":[],"type":"DRUG"}],"last_update":"2024-09-19","lead_sponsor":"Nordic Lymphoma Group","official_title":"R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS).","timeFrame":"2 years."}],"references":[],"start_date":{"date":"2020-08-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT04332822"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/polar-bear-nct04332822"}